神經肌肉疾病

互動

閱讀原文引述

在2025年12月舉行的CONITEC〔Comissão Nacional de Incorporação de Tecnologias no SUS——全國衛生技術納入委員會〕會議上代表SMA〔脊髓性肌肉萎縮症〕患者發聲；就CONITEC關於SMA治療報銷的初步報告提交回應及建議；以及動員公眾參與公開諮詢。

Representação de pacientes com AME na reunião da Conitec ocorrida em dezembro de 2025; respostas e recomendações aos relatórios preliminares da Conitec sobre incorporação de medicamentos para AME; mobilização popular para consultas públicas.

互動

閱讀原文引述

我們曾在FDA（食品及藥物管理局）顧問委員會上作證，並協助籌辦以患者為中心的藥物開發會議。

We have testified at FDA Adcomms and have helped organize Patient-Focused Drug Development meetings; we also regularly submit comments in response to FDA RFIs.

行動與倡議

閱讀原文引述

大力倡導爭取治療機會，並推動將脊髓性肌肉萎縮症（SMA）納入新生兒篩查項目。

Heavily advocated for access to treatment and then for SMA to be added to the Newborn Screening Panel. Still advocate for adult access, but there has been less opportunity. I have personally also advocated for better access overall to medicines, as it always felt wrong to try and compete for standard of care treatments.

行動與倡議

閱讀原文引述

就獲取Qalsody（托非森）採取法律行動——該療法已獲FDA（美國食品及藥物管理局）及EMA（歐洲藥品管理局）批准——用於治療與SOD1基因突變相關的家族性肌萎縮性脊髓側索硬化症（ALS）。

SOD1 mutasyonlu Ailesel ALS hastalığı için FDA, EMA onayı almış Tofersen (Qalsody) ilacına erişim konusunda hukuksal mücadele.